Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Research Square
|
July 9, 2024
Mortality Risk Assessment Using the REVEAL 2.0 Score in Pulmonary Hypertension Secondary to Left Heart Disease
Demetrio Sharp-Dimitri, Mahyar Pourriahi, Christine Zhou, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 12, 2021
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
Steven D Nathan, Victor F Tapson, Jean Elwing, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
November 16, 2025
Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension
Vallerie V McLaughlin, Luke Howard, Jean Elwing, et al.
Advances in Therapy
|
February 2, 2026
Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy
Daniel Lachant, Amresh Raina, Mrinalini Krishnan, et al.
Chest
|
September 17, 2022
Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes
Steven D Nathan, Chunqin Deng, Christopher S King, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 19, 2020
Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Jeff Min, David Badesch, Murali Chakinala, et al.
Chest
|
December 2, 2024
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities
R James White, Karim El-Kersh, Stephan Rosenkranz, et al.
Advances in Therapy
|
December 6, 2023
Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension
Ekkehard Grünig, Franck Rahaghi, Jean Elwing, et al.
Pulmonary Circulation
|
May 9, 2023
Impact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry
Megan Mayer, David B Badesch, Kelly H Nielsen, et al.
Pulmonary Circulation
|
July 10, 2025
Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry
Arun Jose, Athiththan Yogeswaran, Meike Fuenderich, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Research Square
|
July 9, 2024
Mortality Risk Assessment Using the REVEAL 2.0 Score in Pulmonary Hypertension Secondary to Left Heart Disease
Demetrio Sharp-Dimitri, Mahyar Pourriahi, Christine Zhou, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 12, 2021
Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial
Steven D Nathan, Victor F Tapson, Jean Elwing, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation
|
November 16, 2025
Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extension
Vallerie V McLaughlin, Luke Howard, Jean Elwing, et al.
Advances in Therapy
|
February 2, 2026
Efficacy and Safety of Oral Treprostinil in Patients with Pulmonary Arterial Hypertension on Background Monotherapy or Dual Therapy
Daniel Lachant, Amresh Raina, Mrinalini Krishnan, et al.
Chest
|
September 17, 2022
Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes
Steven D Nathan, Chunqin Deng, Christopher S King, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 19, 2020
Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Jeff Min, David Badesch, Murali Chakinala, et al.
Chest
|
December 2, 2024
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities
R James White, Karim El-Kersh, Stephan Rosenkranz, et al.
Advances in Therapy
|
December 6, 2023
Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension
Ekkehard Grünig, Franck Rahaghi, Jean Elwing, et al.
Pulmonary Circulation
|
May 9, 2023
Impact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association Registry
Megan Mayer, David B Badesch, Kelly H Nielsen, et al.
Pulmonary Circulation
|
July 10, 2025
Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry
Arun Jose, Athiththan Yogeswaran, Meike Fuenderich, et al.
Page
of 3